Skip to main content

Treatment Clinical Trials for Colon Cancer

Review the colon cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 34

Using Cancer Cells in the Blood (ctDNA) to Determine the Type of Chemotherapy that will Benefit Patients who Have Had Surgery for Colon Cancer, (CIRCULATE-NORTH AMERICA)
Status: Active
Location: 954 locations
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Status: Active
Location: 21 locations
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Status: Active
Location: 17 locations
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Status: Active
Location: 15 locations
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Status: Active
Location: 14 locations
Evaluate REC-4881 in Patients With FAP
Status: Active
Location: 6 locations
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Status: Active
Location: 6 locations
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Status: Active
Location: 6 locations
TAS-102 Combined with Alternating Oxaliplatin and Irinotecan (Sequential TASOXIRI) with or without Bevacizumab for the Treatment of Refractory and Metastatic Colorectal Cancer
Status: Active
Location: 5 locations
Cemiplimab for the Treatment of Localized dMMR Colon Cancer, Phoenix Trial
Status: Active
Location: 4 locations
Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer
Status: Active
Location: 3 locations
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Status: Active
Location: 3 locations
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Status: Active
Location: 3 locations
Neratinib and Trastuzumab Deruxtecan for the Treatment of HER2 Overexpressing Unresectable or Metastatic Gastrointestinal Cancer
Status: Active
Location: 3 locations
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
Status: Active
Location: 2 locations
Atezolizumab with Capecitabine and Oxaliplatin Before Surgery for the Treatment of Resectable Non-Metastatic Proficient Mismatch Repair Colon Cancer, NICER Trial
Status: Active
Location: 2 locations
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Status: Active
Location: 5 locations
Transcriptional and Immune Targets of Vitamin D in Patients with Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Cholecalciferol
Status: Active
Location: 2 locations
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Immunotherapy (Dostarlimab) for the Treatment of Stage II and III Deficient Mismatch Repair Colon Cancer
Status: Active
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
Inhalational or Intravenous Anesthesia during Surgery for Patients with Colon Cancer, VIVA Study
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
ctDNA-Directed Chemotherapy after Hepatectomy for the Treatment of Colorectal Liver Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Avutometinib, Defactinib and Cetuximab for the Treatment of Patients with Unresectable or Metastatic, Refractory Colorectal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland